Aoxing Pharmaceutical Company (AXN)
Aoxing Pharmaceutical Company Revenue Growth: 10.97%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AXN Revenue Growth Rankings
| Overall | 61st percentile | 1675 of 4358 |
| Sector | 54th percentile | 206 of 456 in Healthcare |
| Industry | 66th percentile | 6 of 18 in Drug Manufacturers - Major |
AXN Revenue Growth Range, Past 5 Years
| Minimum | -63.67% | Jun 2009 |
| Maximum | 284.5% | Jun 2008 |
| Average | 44.15% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AXN related companies
AXN News
$AXN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3ydK
about 3 days ago by MarketBrief
about 3 days ago by MarketBrief
Aoxing Pharmaceutical Company Announces Third Quarter Fiscal 2012 Financial and Operational Results
May 15, 8:02PM Marketwire
May 15, 8:02PM Marketwire
Aoxing Pharmaceutical Company Appoints BDO China Dahua as Its Independent Auditor
Mar 22, 4:15PM Benzinga
Mar 22, 4:15PM Benzinga
Aoxing Pharmaceutical Company Announces Second Quarter Fiscal 2012 Financial and Operational Results
Feb 14, 5:00PM Marketwire
Feb 14, 5:00PM Marketwire
Aoxing Pharmaceutical Company Announces First Quarter Fiscal 2012 Financial and Operational Results
Nov 15, 8:15AM PR Newswire
Nov 15, 8:15AM PR Newswire
Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China
Nov 03, 5:01PM Benzinga
Nov 03, 5:01PM Benzinga
Aoxing Pharmaceutical Company Announces Fiscal Year 2011 Financial and Operational Results
Sep 28, 11:18PM Marketwire
Sep 28, 11:18PM Marketwire
Aoxing Pharmaceutical Company to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 08, 7:30AM PR Newswire
Sep 08, 7:30AM PR Newswire
Someone is playing with $AXN. Notice the wide daily swings. http://chart.ly/ywkmnlw
about 333 days ago by cougarhsv
about 333 days ago by cougarhsv
$AXN had 2 insider purchases last week. It's up from 0.94 to 1.56 , made it to $YHOO top movers list. #WatchInsiders
about 335 days ago by WatchInsiders
about 335 days ago by WatchInsiders
$AXN $1.11 Zhang Guoan officer (Senior VP of Finance) P 51,300 @ $0.96 amnt $49,259 proc'd $7,692 6/20/2011
about 342 days ago by canarionyc
about 342 days ago by canarionyc
$AXN $0.98 Zhang Guoan officer (Senior VP of Finance) P 47,000 @ $0.95 amnt $44,641 proc'd $1,410 6/17/2011
about 345 days ago by canarionyc
about 345 days ago by canarionyc
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Midazolam Maleate Oral Film
Jun 17, 2:08PM PR Newswire
Jun 17, 2:08PM PR Newswire
Aoxing Pharmaceutical Company Announces Details of Its 2011 Annual Meeting of Stockholders
Jun 13, 8:30AM PR Newswire
Jun 13, 8:30AM PR Newswire
Aoxing announces issuance of Chinese patent for Naloxone sublingual film
May 02, 10:15AM FlyOnTheWall
May 02, 10:15AM FlyOnTheWall
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
May 02, 9:00AM PR Newswire
May 02, 9:00AM PR Newswire
$AXN OSHEA JOHN P director B 7,205 @ $2.59 totl $18,660.90 1/19/2011 . 1st ins trans in Aoxing. #secfilings
about 493 days ago by canarionyc
about 493 days ago by canarionyc
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AXN | 0.32 | -0.02 | -7.11% | 15.81M |
| AXL | 9.32 | -0.09 | -0.96% | 698.81M |
| AXK | 2.73 | -0.03 | -1.09% | 30.30M |
| AXJL | 57.50 | -0.53 | -0.91% | |
| AXFN | 20.75 | +0.00 | +0.00% | |
| AXE | 58.43 | -0.07 | -0.12% | 1.932B |
| AXDI | 56.32 | +0.00 | +0.00% | |
| AXAS | 2.56 | -0.07 | -2.66% | 236.19M |
| AWX | 3.47 | -0.06 | -1.70% | 11.07M |
| AWRE | 5.57 | -0.14 | -2.45% | 115.30M |
